Law ❯ Litigation ❯ Class Action ❯ Securities Fraud

False Statements

Multiple Firms Seek Lead Role in Gossamer Bio Securities Suit After PROSERA Miss

Law firms say the company concealed trial‑design and site‑monitoring problems that plaintiffs blame for the failed Phase 3 result and heavy investor losses.

10 ARTICLES

last mo.

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

12 ARTICLES

2mo ago

ImmunityBio Files FDA Response on Anktiva Ads as Investor Suits Build

4 ARTICLES

4mo ago

BellRing Investors Urged to Seek Lead-Plaintiff Status as March 23 Deadline Nears

3 ARTICLES

4mo ago

Law Firms Seek Lead Plaintiffs in Ramaco Securities Case Over Brook Mine Disclosures

3 ARTICLES

4mo ago

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

6 ARTICLES

6mo ago

Inspire Medical Faces Securities Class Action Over Inspire V Rollout as Lead‑Plaintiff Deadline Nears

5 ARTICLES

6mo ago

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

11 ARTICLES

7mo ago

CarMax Securities Class Period Extended to Nov. 5 as Firms Press Jan. 2 Lead-Plaintiff Deadline